Small Cell Lung Cancer News

Maintenance Pazopanib Provides PFS, not OS, Benefit in Small-cell Lung Cancer - Cancer Therapy Advisor



Cancer Therapy Advisor
 
Maintenance Pazopanib Provides PFS, not OS, Benefit in Small-cell Lung Cancer 
Cancer Therapy Advisor
Pazopanib maintenance therapy prolonged progression-free survival (PFS), but not overall survival (OS), among patients with extensive-disease small-cell lung cancer (ED-SCLC), according to a study presented at the International Association for the ...
Socioeconomic factors influence non-small cell lung cancer survival Healio
World Conference on Lung Cancer Tuesday Press Conference: Evidence to Support Innovative Lung Cancer ... GlobeNewswire (press release)
Hutchison China, AstraZeneca Say Drug Shows Potential to Treat Lung Cancer Fox Business
Nasdaq  -Business Wire (press release)  -Interactive Investor 
all 13 news articles » 


Where there's smoke... - Nature.com



Nature.com
 
Where there's smoke... 
Nature.com
A new study, recently published in Cancer Cell, demonstrates that chronic smoking elicits progressive changes in histone and DNA methylation patterns, which can sensitize lung epithelial cells to form tumours in response to a single oncogenic event.

 


Rapidly Progressing Advanced Non-Small Cell Lung Cancer ... - PR Newswire (press release)



Rapidly Progressing Advanced Non-Small Cell Lung Cancer ... 
PR Newswire (press release)
INDIANAPOLIS, Oct. 16, 2017 /PRNewswire/ -- New subgroup analysis from Eli Lilly and Company's (NYSE: LLY) Phase 3 REVEL trial of CYRAMZAź ...

and more » 


Patients With Early Small Cell Lung Cancer Respond Favorably to ... - AJMC.com Managed Markets Network



Lung Disease News
 
Patients With Early Small Cell Lung Cancer Respond Favorably to ... 
AJMC.com Managed Markets Network
The study showed that using tumor mutation burden (TMB) can be beneficial for predicting patient response to the combination of 2 immuno-oncology therapies.
Opdivo, Alone or Combined with Yervoy, Extends Lung Cancer Patients' Survival, Phase 1/2 Trial Shows Lung Disease News
Combo of Bristol-Myers' Opdivo and Yervoy shows treatment benefit ... Seeking Alpha
BMS scores an early victory in the new cancer biomarker battle ... pharmaphorum (blog)

all 6 news articles » 


Apatinib plus icotinib in treating advanced non-small cell lung cancer after icotinib treatment failure: a ... - Dove Medical Press



Apatinib plus icotinib in treating advanced non-small cell lung cancer after icotinib treatment failure: a ... 
Dove Medical Press
Background: Treatment failure frequently occurs in patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) who respond to EGFR tyrosine kinase inhibitors initially. This retrospective study tried to investigate ...

 


3 Things In Biotech You Should Learn Today: October 17, 2017 - Seeking Alpha



Seeking Alpha
 
3 Things In Biotech You Should Learn Today: October 17, 2017 
Seeking Alpha
News: BMY announced findings from the CheckMate-032 study in patients with small cell lung cancer, specifically in terms of efficacy for the combination of nivolumab and ipilimumab, depending on patient tumor mutation burden status. Patients with "high ...

 


Nivolumab/Ipilimumab Combo Active in SCLC With High Tumor Burden - OncLive



OncLive
 
Nivolumab/Ipilimumab Combo Active in SCLC With High Tumor Burden 
OncLive
The combination of nivolumab (Opdivo) and ipilimumab (Yervoy) induced an objective response rate (ORR) of 46% in patients with recurrent small cell lung cancer (SCLC) with high tumor mutation burden (TMB), according to an exploratory analysis from the ...

 


Radiation Therapy Increases 5-year Rate of Cardiac Events in Small ... - Cancer Therapy Advisor



Cancer Therapy Advisor
 
Radiation Therapy Increases 5-year Rate of Cardiac Events in Small ... 
Cancer Therapy Advisor
Researchers analyzed the outcomes of 7060 patients with SCLC from the SEER database to determine the rates of new CEs.

and more » 


AstraZeneca files Imfinzi for groundbreaking lung cancer use - pharmaphorum (blog)



pharmaphorum (blog)
 
AstraZeneca files Imfinzi for groundbreaking lung cancer use 
pharmaphorum (blog)
AstraZeneca has filed Imfinzi in a new earlier setting to treat non-small cell lung cancer, setting it up for an expected blockbuster niche in treating the disease. The FDA has now accepted a filing for Imfinzi (durvalumab) for patients with locally ...
AstraZeneca's Imfinzi gets speedy US review for lung cancer PharmaTimes
US FDA Accepts Supplemental Biologics License Application for IMFINZI Business Wire (press release)
AstraZeneca's Imfinzi cancer drug clears another regulatory hurdle Proactive Investors UK
Nasdaq  -Stock Market Wire 
all 11 news articles » 


Inivata Highlights New Clinical Data on InVision(TM) ctDNA Liquid Biopsy Platform in advanced NSCLC at WCLC 2017 - GlobeNewswire (press release)



Inivata Highlights New Clinical Data on InVision(TM) ctDNA Liquid Biopsy Platform in advanced NSCLC at WCLC 2017 
GlobeNewswire (press release)
The study involved a blind retrospective evaluation of Inivata's InVision ctDNA liquid biopsy analysis to characterize and monitor the molecular profile of advanced non-small cell lung cancer (NSCLC) during genotype-directed therapy with osimertinib ...

and more »